Acrivon is a startup based in the United States.
Acrivon develops targeted precision oncology therapies using its proprietary AP3 platform to match drug mechanisms with the biological drivers of cancer, focusing on DNA damage response and kinase inhibitors in clinical development.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.